Pharmaceutical company Gilead Sciences has refused to directly sell its HIV prevention drug to Doctors Without Borders.
The move came after months of talks in which Doctors Without Borders asked Gilead Sciences for a “limited” supply of ...
Gilead plans to develop Ouro’s lead drug candidate, gamgertamig, alongside a Belgian pharma company.
By Mariam Sunny March 23 (Reuters) - Gilead Sciences said on Monday it would buy privately held biotech firm Ouro Medicines ...
New collaboration structure achieves meaningfully improved financial terms and flexibility for Galapagos Following this transaction, the Company ...
Preview this article 1 min A humanitarian group says the company’s supply efforts aren’t meeting the moment. How AI is ...
Gilead Sciences is paying $1.67 billion for a T-cell engager (TCE) company via a front-loaded deal that could also give new ...
Gilead Sciences plans to acquire Ouro Medicines for up to about $2.18 billion and develop the assets from the deal in a ...
Galapagos (NASDAQ:GLPG) said it has entered into a binding collaboration agreement with Gilead focused on Gamgertamig, a BCMA ...
Gilead Sciences (GILD) closed the most recent trading day at $139.37, moving +2.22% from the previous trading session. This move lagged the S&P 500's daily gain of 2.91%. Meanwhile, the Dow gained ...
Galapagos (GLPG) backs Gilead’s Ouro Medicines deal, sharing $1.675B upfront and milestones, plus 20–23% royalties on gamgertamig—read more.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results